Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application.
MEDICC Rev
; 9(1): 16-22, 2007 10.
Article
em En
| MEDLINE
| ID: mdl-21487356
ABSTRACT
This paper reviews 20 years of experience and scientific contributions of the Cuban meningococcal BC vaccine (VA-MENGOC-BC®) obtained by the Finlay Institute in Havana, Cuba. The vaccine is the first of its type in the world that is safe, effective, and commercially available for preventing meningococcal disease caused by serogroup B meningococcus; it is also effective against serogroup C. VA-MENGOC-BC® has shown satisfactory results, with no serious adverse events, after application of approximately 55 million doses in some 15 countries. Also included is background information on meningococcal disease, as well as the main characteristics of VA-MENGOC-BC®, the strategy used for controlling meningococcal disease and its prevention in Cuba, and a summary of the main scientific results obtained in basic research, development, clinical evaluation, and post-marketing results (safety, efficacy-effectiveness, post-vaccination adverse events, etc.) in Cuba and elsewhere.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
País/Região como assunto:
Cuba
Idioma:
En
Revista:
MEDICC Rev
Assunto da revista:
SAUDE PUBLICA
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Cuba